Literature DB >> 22915608

Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum.

Ken B Waites1, Lynn B Duffy, Cécile M Bébéar, Anne Matlow, Deborah F Talkington, George E Kenny, Patricia A Totten, Donald J Bade, Xiaotian Zheng, Maureen K Davidson, Virginia D Shortridge, Jeffrey L Watts, Steven D Brown.   

Abstract

An international multilaboratory collaborative study was conducted to develop standard media and consensus methods for the performance and quality control of antimicrobial susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum using broth microdilution and agar dilution techniques. A reference strain from the American Type Culture Collection was designated for each species, which was to be used for quality control purposes. Repeat testing of replicate samples of each reference strain by participating laboratories utilizing both methods and different lots of media enabled a 3- to 4-dilution MIC range to be established for drugs in several different classes, including tetracyclines, macrolides, ketolides, lincosamides, and fluoroquinolones. This represents the first multilaboratory collaboration to standardize susceptibility testing methods and to designate quality control parameters to ensure accurate and reliable assay results for mycoplasmas and ureaplasmas that infect humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915608      PMCID: PMC3486213          DOI: 10.1128/JCM.01439-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  4 in total

1.  Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing.

Authors:  John Turnidge; Gerry Bordash
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

2.  Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp.

Authors:  Li Xiao; Donna M Crabb; Lynn B Duffy; Vanya Paralanov; John I Glass; Daniel L Hamilos; Ken B Waites
Journal:  Int J Antimicrob Agents       Date:  2011-02-24       Impact factor: 5.283

3.  Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma species in the United States.

Authors:  Li Xiao; Donna M Crabb; Lynn B Duffy; Vanya Paralanov; John I Glass; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro.

Authors:  R L Jao
Journal:  Am J Med Sci       Date:  1967-06       Impact factor: 2.378

  4 in total
  26 in total

1.  Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans.

Authors:  Ankit Bharat; Scott A Cunningham; G R Scott Budinger; Daniel Kreisel; Charl J DeWet; Andrew E Gelman; Ken Waites; Donna Crabb; Li Xiao; Sangeeta Bhorade; Namasivayam Ambalavanan; Daniel F Dilling; Erin M Lowery; Todd Astor; Ramsey Hachem; Alexander S Krupnick; Malcolm M DeCamp; Michael G Ison; Robin Patel
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

Review 2.  The Brief Case: Mycoplasma hominis Extragenital Abscess.

Authors:  Sarah Stabler; Emmanuel Faure; Claire Duployez; Frédéric Wallet; Rodrigue Dessein; Rémi Le Guern
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

3.  16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

Authors:  E Amram; I Mikula; C Schnee; R D Ayling; R A J Nicholas; R S Rosales; S Harrus; I Lysnyansky
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

4.  Antibacterial Resistance in Ureaplasma Species and Mycoplasma hominis Isolates from Urine Cultures in College-Aged Females.

Authors:  Marissa A Valentine-King; Mary B Brown
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

6.  Tetracycline Resistance Mediated by tet(M) Has Variable Integrative Conjugative Element Composition in Mycoplasma hominis Strains Isolated in the United Kingdom from 2005 to 2015.

Authors:  Victoria J Chalker; Martin G Sharratt; Christopher L Rees; Oliver H Bell; Edward Portal; Kirsty Sands; Matthew S Payne; Lucy C Jones; Owen B Spiller
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

7.  Therapeutic Drug Monitoring of Moxifloxacin to Guide Treatment of Mycoplasma hominis Meningitis in an Extremely Preterm Infant.

Authors:  Telford Yeung; Erin Chung; Jennifer Chen; Laura K Erdman; Mina Smiljkovic; Waison Wong; Asaph Rolnitsky; Shaun K Morris; Amr El Shahed; Rudaina Banihani; Ari Bitnun; Christopher Tomlinson
Journal:  J Pediatr Pharmacol Ther       Date:  2021-11-10

Review 8.  Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update.

Authors:  Rose Marie Viscardi; Suhas G Kallapur
Journal:  Clin Perinatol       Date:  2015-10-09       Impact factor: 3.430

9.  Brain abscess caused by Ureaplasma urealyticum in an adult patient.

Authors:  Philipp Deetjen; Christoph Maurer; Andreas Rank; Ansgar Berlis; Sören Schubert; Reinhard Hoffmann
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

10.  Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013.

Authors:  Michael L Beeton; Victoria J Chalker; Lucy C Jones; Nicola C Maxwell; O Brad Spiller
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.